Compass Therapeutics Announced Statistically Significant Top-line Data On The Primary Efficacy Endpoint For COMPANION-002, The Company's Ongoing Phase 2/3 Trial Of Tovecimig (Formerly CTX-009) In Combination With Paclitaxel In Patients With Advanced Biliary Tract Cancer

Author: Benzinga Newsdesk | April 01, 2025 07:07am

• Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting.
• The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.
• The study also showed differences between treatment arms for other efficacy measures, including progressive disease (PD) rates of 16.2% in patients on tovecimig in combination with paclitaxel versus 42.1% in patients on paclitaxel alone.
• The pre-specified number of events required to trigger the analyses of the secondary endpoints, including progression free survival (PFS), overall survival (OS) and duration of response (DoR), has not yet been met due to fewer of these events occurring than were originally modeled. The Company expects to report these endpoints in Q4 of this year.

Posted In: CMPX